| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
IND Filing example | IND | — | Subscribe to access the data. | Cell Therapies | Endocrine System | ||
IND Filing example | IND | — | Subscribe to access the data. | Cell Therapies | Endocrine System | ||
IND Filing example | IND | — | Subscribe to access the data. | Cell Therapies | Endocrine System |
Recent Updates
Recently added Catalysts
Century Therapeutics, Inc.$2.25
-0.07 (-3.03%)
D 27Pipeline Score Richly Valued Biotech · Commercial
Market Cap
407.60 M
EPS
-1.11
P/E Ratio
-
Value Trade
3.77 M
SEC Financials
Q1 2026Dilution Risk
25%R&D Expenses
17.11 M
Operating CF
-25.26 M
Total Assets
326.55 M
Total Liabilities
61.81 M
Equity
264.74 M
D/E Ratio
12,345
-2.16 %
Week
-2.16 %
1 Month
6.6 %
3 Month
361.22 %
6 Month
-88.41 %
5 Year
-88.41 %
All Time
Cash Data
Cash Position
134.80 M
Monthly Burn
8.42 M
Runway
14.3 mo
Burn Trend
StableSEC Filing
May 13, 2026
Overview
Volume
1.21 M
52 Week Range
0.44 - 3.04
% held by Insiders
32.28 %
% held by Institutions
56.28 %
Enterprise Value
320.47 M
Total Shares
179.63 M
Short %
32.48 %
Float Shares
72.21 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Century Therapeutics, Inc.
266Total events
5Upcoming
26Tier-1 (high impact)
2021 – 2027Coverage
Upcoming catalysts 5
Q4 2027
T2Runway Guidance Update
Cash runway extended beyond planned key clinical milestones (Q4 2027)
Event history 261
Jun 8, 2026
◆Oral PresentationCNTY-813Presentation
Oral presentation of CNTY-813 preclinical data at ADA 86th Scientific Sessions
type 1 diabetessource ↗
May 13, 2026
Mar 12, 2026
Mar 12, 2026
●IND Enabling CompleteCNTY-308Preclinical
CNTY-308 in IND-enabling studies
B-cell-mediated diseasessource ↗
Mar 2026
Jan 12, 2026
Jan 12, 2026
●IND Enabling CompleteCNTY-308Preclinical
CNTY-308 in IND-enabling studies
B-cell-mediated autoimmune diseasessource ↗
Jan 12, 2026
●Enrollment UpdateCNTY-101Trial
Patient enrollment ongoing for CNTY-101 in Phase 1/2 CARAMEL IST
autoimmune diseasesource ↗
Drug Pipeline Intelligence
D27
Pipeline Score $16M
Pipeline ValueRichly Valued
Valuation Signal1
Drugs Scored0.0x
rNPV / MCap Top 29%
Micro Cap (rank 648 of 911)
Percentile RankCentury Therapeutics, Inc. faces pipeline headwinds (27/100), with $72M risk-adjusted pipeline value, led by CNTY-101 in Systemic Lupus Erythematosus (Phase 1).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CNTY-101 Monoclonal antibody | Systemic Lupus Erythematosus | Phase 1 | NCT06255028 | 18% | $72M | ACTIVE NOT_RECRUITING | 6 | STALLED | D (36) | Aug 1, 2028 | HIGH_RISK | LOW May 26, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
CNTY-101 | R/R B-cell lymphomas | Phase 1 | 2025-01-13 | 83% overall response rate | January 2025 Corporate Overview 2 Forward-looking statements This presentation contains forward-looking statements within the meaning of, and made pursuant to the safe harbor provisions of, The Private Securities Litigat Read More | |
CNTY-101 | R/R B-cell lymphomas | Phase 1 | 2025-01-13 | 83% overall response rate | January 2025 Corporate Overview 2 Forward-looking statements This presentation contains forward-looking statements within the meaning of, and made pursuant to the safe harbor provisions of, The Private Securities Litigat Read More | |
CNTY-101 | R/R B-cell lymphomas | Phase 1 | 2025-01-13 | 83% overall response rate | January 2025 Corporate Overview 2 Forward-looking statements This presentation contains forward-looking statements within the meaning of, and made pursuant to the safe harbor provisions of, The Private Securities Litigat Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in IPSC
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
IPSC Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-07-17 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-07-17 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-07-17 | 0.00 | 0 | - | - | - | - | - | - | ||||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
IPSC▼ -3%today
Century Therapeutics Selected for Oral Presentations of CNTY-813 Preclinical Data at EASD 2026 and Breakthrough T1D® Clinical & Research Congress 2026
Century Therapeutics has announced that its CNTY-813 preclinical data will be presented at two major scientific congresses in 2026. The presentations will focus on CNTY-813, an iPSC-derived islet replacement therapy designed for type 1 diabetes, utilizing the company's Allo-Evasion™ technology. This therapy aims to provide durable engraftment without the need for chronic immunosuppression, addressing a significant limitation in current treatments.
Read more →IPSCNew CNTY-813 Preclinical Data Demonstrate Durable Glucose Control, Immune Evasion Under Alloimmune Pressure, and Scalable Manufacturing at ADA 2026
Century Therapeutics presented promising preclinical data for CNTY-813, an iPSC-derived islet replacement therapy, at the ADA 2026. The therapy demonstrated durable glucose control for over eight months and maintained insulin secretion under immune pressure without the need for immunosuppression. The company is on track for an IND submission in Q4 2026 and expects initial clinical data in H2 2027.
Read more →IPSCCentury Therapeutics Reports First Quarter Financial Results and Business Updates
Century Therapeutics reported its first quarter financial results, highlighting progress in its pipeline, particularly CNTY-813 for type 1 diabetes, which is on track for an IND submission by Q4 2026. The company also plans to present preclinical data at the ADA annual Scientific Sessions in June 2026. Additionally, CNTY-308 is set to advance into clinical trials this year. Century's financial position is strong, with sufficient cash reserves to support operations until 2029.
Read more →IPSCCentury Therapeutics Selected for Oral Presentation of CNTY‑813 Preclinical Data at the American Diabetes Association 86th Scientific Sessions
Century Therapeutics, Inc. (NASDAQ: IPSC) announced that they will present preclinical data for CNTY-813 at the upcoming ADA 86th Scientific Sessions. This therapy aims to provide scalable, off-the-shelf islet cell replacements for patients with type 1 diabetes and significantly reduce the need for chronic immunosuppressive therapy. The oral presentation will take place on June 8, 2026, in New Orleans, Louisiana, highlighting the company's commitment to advancing this innovative therapy. Century's focus on patient access and efficacy reflects its ambitious goals for the future of diabetes treatment.
Read more →IPSC▼ -8.4%on this news
Century Therapeutics Reports Full Year 2025 Financial Results and Business Updates
Century Therapeutics reported its 2025 financial results, highlighting progress in its lead program CNTY-813 for type 1 diabetes, with an IND submission expected in Q4 2026. The company also announced advancements in CNTY-308, a CAR-iT cell therapy, and secured $135 million in funding to support its operations into 2029. Despite a reduced cash position, Century remains optimistic about its pipeline and clinical prospects.
Read more →IPSCCentury Therapeutics to Participate in Upcoming Investor Conferences in March
Century Therapeutics, a biotechnology firm focused on iPSC-derived therapies, announced its participation in several investor conferences in March. The company aims to address autoimmune diseases and cancer through its innovative therapies. Live webcasts of the presentations will be available on their website, with archived replays accessible for 30 days.
Read more →IPSC▲ +5.2%on this news· ran to +19% by day 3
Unlocking the Value of our Pipeline for T1D January 2026 2 Forward - looking statements This presentation contains forward - looking statements within the meaning of, and made pursuant to the safe harbor provisions of, T
Century Therapeutics is advancing their cell therapy pipeline focused on Type 1 Diabetes and other autoimmune diseases, with key programs CNTY-813 and CNTY-308 in IND-enabling studies. They are employing innovative Allo-Evasion technology aimed at enhancing therapeutic persistence and efficacy. The company has extended its cash runway to support its clinical milestones, with initial data expected by 2027. However, successful navigation of regulatory processes and associated risks remain critical to their future outcomes.
Read more →IPSC▲ +36.2%on this news· ran to +65% by day 3shared move
Century Therapeutics Secures Oversubscribed $135 Million Private Placement Financing to Support Lead Program, CNTY-813, a Potentially Curative Therapy for Type 1 Diabetes PHILADELPHIA
Century Therapeutics has announced an oversubscribed private placement financing of approximately $135 million to advance its lead program, CNTY-813, aimed at treating Type 1 diabetes. The investment will help extend the company's cash runway to the first quarter of 2029, with anticipation for an IND submission in 2026 and initial clinical data coming in 2027. The financing was led by new investor TCGX and included participation from other notable investors, emphasizing confidence in the company's innovative cell therapy approach.
Read more →IPSC▼ -5.7%on this news
Advancing Pipeline of Transformative Cell Therapies Corporate Deck – December 2025 2 Forward-looking statements This presentation contains forward-looking statements within the meaning of, and made pursuant to the
Century Therapeutics is advancing its pipeline of transformative cell therapies with several promising candidates approaching clinical trials. Key products include CNTY-101, CNTY-813, and CNTY-308, which are aimed at treating autoimmune diseases and B-cell-mediated conditions. The company boasts a well-established in-house manufacturing facility that significantly improves production efficiency and product quality. Preliminary trial data have shown positive early efficacy, particularly in B-cell depletion in patients with systemic lupus erythematosus. Century's innovative approaches, such as Allo-Evasion technology, hold potential for enhanced persistence of therapies in patients.
Read more →IPSCCentury Therapeutics Appoints Accomplished Biotechnology Leaders Dr. Han Lee and Dr. Martin Murphy to Board of Directors PHILADELPHIA
Century Therapeutics has appointed Dr. Han Lee and Dr. Martin Murphy to its Board of Directors at a critical time for the company. Dr. Lee will serve on the Audit and Compensation Committees while Dr. Murphy will join the Compensation and Nominating Committees. Their extensive experience in biotechnology and corporate development is expected to support Century's efforts to advance its iPSC-derived cell therapies, including CNTY-813 for type 1 diabetes. The company's leadership anticipates that their appointments will help deliver significant value to patients and stakeholders.
Read more →IPSCCentury Therapeutics to Participate in Piper Sandler 37th Annual Healthcare Conference
Century Therapeutics, a biotechnology firm specializing in iPSC-derived cell therapies, will participate in the Piper Sandler 37th Annual Healthcare Conference in New York. Key executives, including Chief Scientific Officer Chad Cowan and CEO Brent Pfeiffenberger, will discuss advancements in cell therapy. They will also participate in a webcasted fireside chat, which will be available on the company's website. This event presents an opportunity for the company to showcase its innovative approaches in treating autoimmune diseases and cancer.
Read more →IPSC▼ -17.5%on this news
Century Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update
Century Therapeutics reported its third quarter 2025 financial results, highlighting advancements in its iPSC-derived therapies. The company is focusing on its beta islet program for Type 1 Diabetes (T1D) and plans to initiate IND-enabling studies by the end of 2025. Additionally, CNTY-308 is set to enter clinical trials next year, supported by promising preclinical data.
Read more →IPSC▼ -17.5%on this newsshared move
Century Therapeutics Announces New Beta Islet Program for Type 1 Diabetes
Century Therapeutics has launched a new program, CNTY-813, targeting Type 1 diabetes using iPSC-derived beta islets. The therapy utilizes proprietary Allo-Evasion™ 5.0 technology to prevent immune rejection, aiming for durable glycemic control without immunosuppression. Preclinical data shows promise, with plans to initiate IND-enabling studies by the end of 2025 and submit an IND application by 2026.
Read more →IPSCCentury Therapeutics to Present at Chardan’s 9th Annual Genetic Medicines Conference
Century Therapeutics, a biotechnology firm specializing in iPSC-derived therapies, announced that its Chief Scientific Officer, Chad Cowan, will present at Chardan’s 9th Annual Genetic Medicines Conference on October 21, 2025. The event will take place in New York, NY, and a live webcast will be available on the company's website. This presentation underscores the company's commitment to addressing autoimmune diseases and cancer through innovative therapies.
Read more →IPSCCentury Therapeutics to Present at H.C. Wainwright 27th Annual Global Investment Conference
Century Therapeutics will present at the H.C. Wainwright 27th Annual Global Investment Conference, with CEO Brent Pfeiffenberger leading the presentation. The event will take place in New York on September 9-10, 2025, and an on-demand webcast will be available starting September 5, 2025. This engagement highlights Century's commitment to advancing its iPSC-derived cell therapy pipeline.
Read more →IPSCCentury Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update Patient dosing ongoing in CALiPSO-1 trial; on track to report clinical data for CNTY-101 in patients with B-cell-mediated au
Century Therapeutics, Inc. has announced its financial results for Q2 2025 and provided a business update. The company continues to execute its clinical program for CNTY-101 in autoimmune diseases while also advancing preclinical studies for CNTY-308. Brent Pfeiffenberger has assumed the role of Board Chair, following a successful term by his predecessor. The firm aims to deliver clinical data for CNTY-101 within 2025, focusing on its innovative iPSC-derived cell therapies.
Read more →IPSCCentury Therapeutics Announces Two Upcoming Presentations at the EULAR 2025 Congress
Century Therapeutics has announced two upcoming presentations at the EULAR 2025 Congress, scheduled for June 11-14, 2025, in Barcelona, Spain. The presentations will focus on their preclinical cell therapy pipeline, particularly CNTY-101, an iPSC-derived CAR-NK product targeting B cell-driven autoimmune diseases. These presentations aim to demonstrate the potential of their therapies in treating serious conditions.
Read more →IPSC▲ +5.8%on this news· ran to +23% by day 3
Century Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update Patient dosing initiated in Phase 1 CALiPSO-1 trial evaluating CNTY-101 in autoimmune disease; expanding to additional U.S. a
Century Therapeutics, Inc. reported positive financial results for the first quarter of 2025, showing a notable increase in collaboration revenue. The company has initiated patient dosing in the Phase 1 CALiPSO-1 trial for CNTY-101 in autoimmune diseases. Century is also expanding its clinical trials to Europe and aims to provide clinical data by the end of 2025. The CEO highlighted ongoing developments in their preclinical pipeline and manufacturing capabilities.
Read more →IPSCCentury Therapeutics Announces Two Upcoming Presentations at the ASGCT 28th Annual Meeting
Century Therapeutics announced two presentations at the ASGCT 28th Annual Meeting, scheduled for May 13-17, 2025. The presentations will focus on their preclinical cell therapy pipeline targeting autoimmune diseases and cancer. Key topics include enhancing solid tumor elimination and generating CAR T cells with effective tumor control. The event will provide insights into Century's innovative approaches in cell therapy.
Read more →IPSCCentury Therapeutics to Host Live Fireside Chat Focused on Newly Prioritized Preclinical Cell Therapy Programs for Autoimmune Diseases and Cancer on Tuesday, April 22, 2025
Century Therapeutics will host a live fireside chat on April 22, 2025, to discuss its preclinical cell therapy programs aimed at autoimmune diseases and cancer. The event will cover investigational therapies such as CNTY-308 and CNTY-341, highlighting the use of advanced iPSC-derived T cells and proprietary immune evasion technology. The chat will be accessible via the company's website.
Read more →IPSCCentury Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update Preclinical pipeline re-prioritization to focus on four potentially transformative programs to advance toward clinic, led by CNTY
Century Therapeutics has reported its full year 2024 financial results, announcing a strategic re-prioritization of its pipeline to focus on four key programs, particularly CNTY-101 for B-cell-mediated autoimmune diseases. The company ended the year with a robust cash position and plans to enhance patient enrollment in clinical trials. However, they have discontinued the Phase 1 ELiPSE-1 trial early, indicating challenges. The company is preparing for a webinar to further discuss their future direction and programs.
Read more →IPSCCentury Therapeutics Announces Investigator-Initiated Phase 1/2 Trial of its iPSC-derived iNK Cell Therapy CNTY-101 in B-cell Mediated Autoimmune Diseases Sponsored by Internationally Renowned Key Opinion Leaders
Century Therapeutics has announced an investigator-initiated Phase 1/2 clinical trial for its iPSC-derived NK cell therapy, CNTY-101, targeting B-cell mediated autoimmune diseases. This trial, named CARAMEL, will be led by key opinion leaders in the field and aims to investigate the safety and efficacy of the therapy in conditions like systemic lupus erythematosus and lupus nephritis. The collaboration represents a significant recognition of CNTY-101's potential, marking the first evaluation of such therapies in this domain. The company anticipates this trial to commence in mid-2025, further expanding their clinical research efforts.
Read more →IPSCJanuary 2025 Corporate Overview 2 Forward-looking statements This presentation contains forward-looking statements within the meaning of, and made pursuant to the safe harbor provisions of, The Private Securities Litigat
Century Therapeutics is emphasizing its advancements in iPSC-derived therapies for cancer and autoimmunity. The company's in-house manufacturing facility aims to enhance production efficiency and product quality. Notably, encouraging clinical data has been reported for CNTY-101, which shows an 83% overall response rate in certain cancer cases. The company ended FY24 with a cash position sufficient to support its operations through 2026 while navigating the complexities of clinical development.
Read more →IPSCCentury Therapeutics to Present at the Piper Sandler 36th Annual Healthcare Conference
Century Therapeutics (NASDAQ: IPSC) will present at the Piper Sandler 36th Annual Healthcare Conference on December 4, 2024, featuring a panel on autoimmune disease cell therapy. Key management team members, including the Chief Scientific Officer and CEO, will discuss the company's advancements in iPSC-derived therapies. The conference provides a platform for Century Therapeutics to showcase its innovative approaches in treating cancer and autoimmune diseases. A live webcast of the discussion will be accessible to the public, highlighting their commitment to patient access in cell therapies.
Read more →IPSC▲ +5.6%on this news
Century Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Updates - Expansion of Phase 1 CALiPSO-1 trial of CNTY-101 in autoimmune disease to include diffuse cutaneous systemic sclerosis and
Century Therapeutics reported its third quarter financial results and highlighted significant advancements in its clinical trials. The company is expanding its Phase 1 CALiPSO-1 trial of CNTY-101 to include additional autoimmune diseases, which is expected to provide insights into its therapeutic potential. In its Phase 1 ELiPSE-1 trial, CNTY-101 demonstrated a high overall response rate and favorable safety profile for patients with r/r B-cell lymphomas. Century aims to advance its pipeline and has secured a robust cash runway, extending into the second half of 2026.
Read more →IPSC▲ +5.6%on this news
Century Therapeutics Announces Upcoming Poster Presentations at the 2024 American Society of Hematology (ASH) Annual Meeting
Century Therapeutics (NASDAQ: IPSC) has announced that they will present preclinical data at the 2024 ASH Annual Meeting in San Diego. The data highlights their iPSC-derived cell therapy programs, which include advancements in CAR T cell functions and gene editing techniques. The company claims to showcase the first iPSC-derived CD4+ and CD8+ CAR T cells that demonstrate function comparable to traditional CAR-T cells. This research underscores their commitment to developing innovative therapies for oncology and autoimmune diseases through iPSC technology.
Read more →IPSCCentury Therapeutics to Present at Guggenheim’s Inaugural Healthcare Innovation Conference
Century Therapeutics (NASDAQ: IPSC) will present at Guggenheim’s Inaugural Healthcare Innovation Conference on November 12, 2024. CEO Brent Pfeiffenberger and CSO Chad Cowan will participate in a fireside chat at 9:30 am ET. This event provides Century Therapeutics a platform to discuss their advancements in induced pluripotent stem cell (iPSC)-derived cell therapies aimed at treating cancer and autoimmune diseases. A live webcast of the event will be available for wider audience access.
Read more →IPSCCentury Therapeutics Strengthens Leadership Team with Appointments of Chief Financial Officer and Chief Scientific Officer
Century Therapeutics has appointed Morgan Conn, Ph.D., as Chief Financial Officer and Chad Cowan, Ph.D., as Chief Scientific Officer, effective October 2024. These strategic appointments aim to bolster the company's leadership team as it advances its clinical programs and expands into additional autoimmune disease indications. Hy Levitsky will transition to an advisory role after contributing significantly to Century as President of Research and Development. The leadership changes reflect Century's commitment to innovation within its iPSC-derived cell therapies.
Read more →IPSCCentury Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Updates - Initiation of Phase 1 CALiPSO-1 Trial of CNTY-101 in Systemic Lupus Erythematosus, marking strategic expansion into autoi
Century Therapeutics reported its second quarter financial results and provided significant updates, including the initiation of the Phase 1 CALiPSO-1 trial for CNTY-101 in systemic lupus erythematosus. This marks a strategic entry into the autoimmune disease sector, along with an expanded cohort for lupus nephritis. The company highlighted promising interim results from its Phase 1 ELiPSE-1 trial for CD19-positive B-cell lymphomas and a solid cash runway extending into 2026. CEO Brent Pfeiffenberger emphasized the progress in their iPSC-derived cell therapy platform and the anticipation of further clinical data by year-end.
Read more →IPSCCorporate Overview July 2024 2 Forward - looking statements This presentation contains forward - looking statements within the meaning of, and made pursuant to the safe harbour provisions of, The Private Securities Litig
Century Therapeutics has provided an overview of its iPSC-derived cell therapy platform, emphasizing its advancements in manufacturing and product development. The company is focused on utilizing its Allo-Evasion TM technology to overcome immune rejection challenges in cell therapies. With well-capitalized initiatives leading into 2026, Century is positioned to achieve clinical milestones and expand its product pipeline. The presentation discusses the inherent risks associated with forward-looking statements, particularly concerning regulatory approvals and operational integration.
Read more →IPSCCentury Therapeutics Presents Interim Results from Phase 1 ELiPSE-1 Study at ASCO 2024 Annual Meeting In ongoing dose escalation, CNTY-101 has demonstrated a manageable safety profile with no observed DLTs or GvHD and wi
Century Therapeutics presented interim results from its Phase 1 ELiPSE-1 study at the ASCO 2024 Annual Meeting. The study evaluated CNTY-101, an investigational iPSC-derived NK cell therapy targeting CD19-positive B-cell malignancies. The results indicated a manageable safety profile with no observed dose-limiting toxicities and preliminary efficacy in heavily pretreated patients. The trial continues to enroll participants and aims to advance into the dose expansion phase soon.
Read more →IPSCCentury Therapeutics Presents Preclinical Data Highlighting Advances in iPSC Platform Technology and Programs at 2024 ASGCT Annual Meeting
Century Therapeutics presented promising preclinical results for CNTY-101, which targets B-cell driven autoimmune diseases at the 2024 ASGCT Annual Meeting. The data highlights CNTY-101's ability to induce CD19-specific cytolysis of B-cells and its potential in treating systemic lupus erythematosus. Additionally, innovative Allo-Evasion™ technology was showcased, which aims to prevent NK cell-mediated rejection of engineered cell therapies. This research underscores Century's commitment to developing enduring and effective cell therapies.
Read more →IPSCCentury Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates - Announced plans to pursue additional autoimmune disease regulatory filings for its iPSC derived NK cell therapy, CNTY-101,
Century Therapeutics reported its financial results for the first quarter of 2024, highlighting significant progress in clinical and operational areas. The company plans to pursue regulatory filings for its iPSC-derived NK cell therapy, CNTY-101, in additional autoimmune diseases beyond systemic lupus erythematosus. Furthermore, Century has closed a $60 million private placement and acquired Clade Therapeutics to bolster its capabilities and pipeline. The firm is also preparing to present new clinical data from its ongoing Phase 1 trial at the upcoming ASCO Annual Meeting.
Read more →IPSCCentury Therapeutics to Present at Chardan’s 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit
Century Therapeutics (NASDAQ: IPSC) announced its upcoming participation in Chardan's 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit. The management team will engage in a virtual fireside chat and participate in a panel discussion focusing on advances in manufacturing for next-generation cell therapies. The events are scheduled for April 30, 2024, and will be available for replay on the company's website. This involvement emphasizes Century's commitment to innovating curative therapies for cancer and autoimmune diseases using iPSC technology.
Read more →IPSC▲ +7.1%on this news
Corporate OverviewApril 2024 2 Forward - looking statements This presentation contains forward - looking statements within the meaning of, and made pursuant to the safe harbour provisions of, The Private Securities Litig
The corporate overview presentation from IPSC outlines their forward-looking statements regarding the potential and strategies for their iPSC-derived cell therapy platform. The document highlights the foundational investments made in technology and manufacturing aimed at driving successful product development. IPSC anticipates advancing differentiated clinical programs and maintaining a strong financial position to support its initiatives. The presentation emphasizes the innovative approaches in gene editing and the extensive capabilities of their manufacturing processes, positioning them favorably in the competitive landscape of cell therapies.
Read more →IPSC▲ +7.1%on this news
Century Therapeutics Strengthens Position in Autoimmune Disease with Strategic Pipeline Expansion Supported by $60 Million Private Placement and Acquisition of Clade Therapeutics Century is pursuing additional autoimmune
Century Therapeutics is enhancing its development in autoimmune diseases through a strategic pipeline expansion supported by a $60 million private placement and the acquisition of Clade Therapeutics. The company plans to advance its CNTY-101 therapy, which is currently undergoing trials for B-cell malignancies and will soon initiate a clinical trial for systemic lupus erythematosus. With the added expertise and programs from Clade, Century aims to broaden its therapeutic offerings and solidify its standing in the iPSC-derived cell therapy space.
Read more →IPSCCentury Therapeutics Presents New Preclinical Data Highlighting iPSC-derived Cell Therapy Platform Technology at the 2024 American Association for Cancer Research (AACR) Annual Meeting PHILADELPHIA
Century Therapeutics announced significant advancements in its iPSC-derived cell therapy platform at the 2024 AACR Annual Meeting. Key presentations highlighted innovative techniques, including a dual-targeting CAR for B cell malignancies and the Allo-Evasion platform for enhanced protection against immune rejection. The data showcased Century's capabilities in gene editing and protein engineering, aiming to improve the effectiveness and safety of allogeneic cell therapies. Additionally, the company is collaborating with multiple donors to advance its clinical programs targeting various cancers and autoimmune disorders.
Read more →IPSCCentury Therapeutics to Present at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference
Century Therapeutics (NASDAQ: IPSC) announced its participation in a fireside chat at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference, scheduled for March 26, 2024. The company specializes in developing induced pluripotent stem cell-derived therapies targeting cancer and autoimmune diseases. A replay of the event will be available for 90 days on the company's website. Century Therapeutics aims to overcome challenges of first-generation cell therapies, enhancing patient access to innovative treatments.
Read more →IPSC▼ -7.2%on this newsshared move
Century Therapeutics Reports Full Year 2023 Financial Results and Provides Business Updates - Presented initial data from Phase 1 ELiPSE-1 Trial of CNTY-101 in relapsed/refractory B-cell lymphomas demonstrating a favorab
Century Therapeutics has reported its full year 2023 financial results and mentioned significant advancements in its clinical trials. Notably, initial data from the Phase 1 ELiPSE-1 trial of CNTY-101 demonstrated encouraging tolerability and early activity in treating relapsed/refractory B-cell lymphomas. The company also received IND clearance for CNTY-101 to treat systemic lupus erythematosus and is set to initiate a Phase 1 clinical trial soon. With a strong financial position, Century is focusing on expanding its iPSC-derived cell therapies for cancer and autoimmune diseases.
Read more →IPSCCentury Therapeutics Announces Six Upcoming Poster Presentations at the 2024 American Association for Cancer Research (AACR) Annual Meeting
Century Therapeutics, a biotechnology firm focused on iPSC-derived therapies, has announced six poster presentations for the 2024 AACR Annual Meeting. The presentations will cover various aspects of their cell therapy platform, including a novel CAR targeting strategy and innovative approaches to immune cell optimization. These presentations reflect the company's ongoing commitment to advancing cancer and autoimmune disease therapies through their unique cell technologies. The event will take place from April 5-10, 2024, in San Diego, CA.
Read more →IPSCCentury Therapeutics to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
Century Therapeutics (NASDAQ: IPSC) has announced its participation in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference, scheduled for February 8th, 2024. The management team will engage in a fireside chat, emphasizing the company's commitment to developing novel iPSC-derived cell therapies. This event will be accessible for replay on the company’s website, reflecting their dedication to keeping investors informed. Century is developing treatments aimed at overcoming limitations of first-generation cell therapies, particularly in oncology and autoimmune conditions.
Read more →IPSCCentury Therapeutics Presents Initial Data from CNTY-101 Phase 1 ELiPSE-1 Trial Supporting the Potential for a Multi-Dosing Strategy for CAR iNK Enabled by Allo-Evasion Edits - Data presented at 65 th ASH Annual Meeting
Century Therapeutics has presented promising initial clinical data from their CNTY-101 Phase 1 ELiPSE-1 trial at the 65th ASH Annual Meeting. The data indicates that CNTY-101, administered at a dose level of 100 million cells, was well tolerated in a heavily pretreated patient with relapsed/refractory B-cell lymphoma. Notably, the patient achieved a six-month durable complete response and displayed no adverse events related to the treatment. Pharmacokinetic analyses also suggest that CNTY-101 may maintain exposure when administered in subsequent cycles without lymphodepletion, supporting the potential for a multi-dosing strategy.
Read more →IPSC▲ +36.1%on this news· ran to +49% by day 3shared move
Century Therapeutics to Host Conference Call to Discuss Preliminary Clinical Data from Phase 1 ELiPSE-1 trial of CNTY-101 in Relapsed or Refractory B-cell Lymphomas and Planned Phase 1 Study in Systemic Lupus Erythematosus
Century Therapeutics will host a conference call on December 11, 2023, to discuss preliminary clinical data from its Phase 1 ELiPSE-1 trial of CNTY-101, which is being tested for relapsed/refractory B-cell lymphomas. The call will feature updated data, including results from different dosing levels, and plans for a Phase 1 study in systemic lupus erythematosus. This marks an important step in the company’s progression towards broader applications of CNTY-101 in both cancer and autoimmune conditions.
Read more →IPSC▲ +36.1%on this news· ran to +49% by day 3shared move
Century Therapeutics Receives FDA Clearance of IND Application for CNTY-101 in Systemic Lupus Erythematosus - Represents second IND clearance for CNTY-101, the Company's lead iPSC-derived CD19-targeted CAR NK cell produc
Century Therapeutics has received FDA clearance for their Investigational New Drug (IND) application for CNTY-101, targeting systemic lupus erythematosus (SLE), marking a pivotal advancement for the company. This IND clearance represents the first for an autoimmune and inflammatory disease for CNTY-101, which features advanced genetic engineering for effective treatment. The company plans to begin a Phase 1 clinical trial in the first half of 2024, with initial data expected by the end of the year. CNTY-101 aims to provide an alternative off-the-shelf cell therapy solution designed to improve patient outcomes in SLE, where traditional therapies have often fallen short.
Read more →IPSCCentury Therapeutics to Present at the Piper Sandler 35th Annual Healthcare Conference
Century Therapeutics (NASDAQ: IPSC) announced that its management will participate in a fireside chat at the Piper Sandler 35th Annual Healthcare Conference scheduled for November 28, 2023. The event will provide insights into the company's advancements in iPSC-derived cell therapies for cancer and autoimmune diseases. A replay of the discussion will be accessible on the company's Investors page for 90 days following the event, promoting transparency and engagement with stakeholders.
Read more →IPSC▼ -13.1%on this news
Century Therapeutics Appoints Brent Pfeiffenberger, Pharm.D., MBA, as Chief Executive Officer
Century Therapeutics has appointed Brent Pfeiffenberger as its new Chief Executive Officer effective December 4, 2023. With over 20 years in the healthcare sector, Pfeiffenberger previously served as COO at Neogene Therapeutics, contributing to its transition to a clinical-stage organization. His appointment is seen as a pivotal move as the company aims to leverage its proprietary platforms to advance allogeneic cell therapies and prepare for its first clinical data readout. Former interim CEO Greg Russotti will transition to a new role focused on technology and manufacturing.
Read more →IPSC▼ -13.1%on this news
Century Therapeutics and FUJIFILM Cellular Dynamics Announce Licenses for the Development and Commercialization of iPSC-Derived Cell Therapies in Autoimmune and Inflammatory Diseases
Century Therapeutics and FUJIFILM Cellular Dynamics have announced a new worldwide license agreement for the development and commercialization of iPSC-derived cell therapies targeting autoimmune and inflammatory diseases. This expansion of their previous collaboration aims to explore treatments for conditions such as type 1 diabetes and multiple sclerosis, leveraging the regenerative properties of iPSCs. The partnership is expected to enhance the development of new immunologic therapies using their existing technology and manufacturing capabilities.
Read more →IPSC▼ -13.1%on this news
Century Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Updates - Brent Pfeiffenberger, Pharm.D., MBA, appointed Chief Executive Officer of Century Therapeutics - - Initial data from the o
Century Therapeutics has announced its third quarter 2023 financial results and key business updates, including the appointment of Brent Pfeiffenberger as CEO. The company reported progress on its Phase 1 ELiPSE-1 trial for CNTY-101, with initial data to be shared at the upcoming ASH Annual Meeting. They also expanded their license agreement with FUJIFILM Cellular Dynamics to bolster their iPSC-derived cell therapy initiatives. Despite a decline in collaboration revenue and cash reserves, Century Therapeutics maintains a strong financial position with $284.3 million available until 2026.
Read more →IPSCCentury Therapeutics to Present Initial Clinical Data Supporting the Potential for a Multi-Dosing Strategy for CAR iNK Enabled by Allo-Evasion™ Edits at the 65th ASH Annual Meeting and Exposition
Century Therapeutics will present initial clinical data for CNTY-101, an allogeneic CAR iNK cell therapy targeting CD19 in relapsed/refractory B-cell lymphomas, at the upcoming ASH Annual Meeting. Preliminary results from the Phase 1 ELiPSE-1 trial demonstrate a complete response in a patient after four 28-day treatment cycles. CNTY-101 is noteworthy for being well tolerated, and it is the first such therapy to be administered in multiple doses without lymphodepletion, which commonly carries significant toxicity. The data underline the potential effectiveness of the company's Allo-Evasion technology for enhancing therapeutic outcomes.
Read more →IPSC▼ -7.4%on this news
Corporate Overview Aug 2023 2 Forward - looking statements This presentation contains forward - looking statements within the meaning of, and made pursuant to the safe harbour provisions of, The Private Securities Litiga
The corporate overview presentation for IPSC highlights its focus on developing iPSC technology and next-generation cell therapies. They reported having a cash runway into 2026 and emphasized their foundational investments in gene editing and manufacturing capabilities. Although the company demonstrated substantial progress, it acknowledged the inherent risks and uncertainties related to its forward-looking statements and reliance on third-party collaborations.
Read more →IPSCCentury Therapeutics to Present at the Chardan 7th Annual Genetic Medicines Conference
Century Therapeutics (NASDAQ: IPSC) announced participation in the Chardan 7th Annual Genetic Medicines Conference, scheduled for October 3, 2023. Interim CEO Greg Russotti, Ph.D., will engage in a fireside chat during the event. This participation underscores the company's commitment to advancing its iPSC-derived cell therapies aimed at treating cancers. A replay of the event will be available on the company’s investor relations website for 90 days following the conference.
Read more →IPSCCentury Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Updates - Company remains on track to report initial data from Schedule A of the ongoing Phase 1 ELiPSE-1 trial of CNTY-101 in rela
Century Therapeutics has announced its financial results for the second quarter of 2023, revealing a cash position of $301 million with expectations of funding operations into 2026. The company is advancing its Phase 1 ELiPSE-1 trial for CNTY-101, targeting relapsed/refractory CD19 positive B-cell lymphomas, and anticipates initial data by the end of the year. Despite facing financial losses, Century maintains confidence in its innovative cell therapy approaches which aim to address cancer treatment challenges.
Read more →IPSCCentury Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Updates - Preclinical data supporting selection of CNTY-101 as lead product candidate presented at AACR Annual Meeting - - Company r
Century Therapeutics reported its financial results for Q1 2023, highlighting a net loss of $31.3 million but a strong cash position of $334.8 million expected to last into 2026. The company announced that preclinical data supports CNTY-101 as its lead candidate, and it remains on track to release initial clinical trial data by the end of the year. Century Therapeutics focuses on developing innovative iPSC-derived cell therapies tailored for cancer treatments, aiming to overcome challenges faced by first-generation therapies.
Read more →IPSCCentury Therapeutics to Present at Chardan’s 7th Annual Genetic Medicines & Cell Therapy Manufacturing Virtual Summit
Century Therapeutics announced that their CEO, Greg Russotti, will participate in a fireside chat at Chardan’s 7th Annual Genetic Medicines & Cell Therapy Manufacturing Virtual Summit on April 24, 2023. The company, which specializes in developing induced pluripotent stem cell (iPSC)-derived therapies, aims to advance cancer treatment by overcoming limitations of traditional cell therapies. A replay of the event will be available afterward on their investors' page. Century Therapeutics emphasizes its commitment to accessible, off-the-shelf cell therapies.
Read more →IPSC▼ -7.9%on this newsshared move
Century Therapeutics Announces Leadership Changes
Century Therapeutics has announced significant leadership changes, with Greg Russotti stepping in as the ad-interim Chief Executive Officer following Lalo Flores' departure. Michael C. Diem has been promoted to Chief Financial Officer, while Hy Levitsky rejoins as President of Research and Development. The Board is actively searching for a permanent CEO, as the company prepares for a new phase of growth in cell therapy.
Read more →IPSCCorporate Overview March 2023 2 Forward-looking statements This presentation contains forward-looking statements within the meaning of, and made pursuant to the safe harbour provisions of, The Private Securities Litigati
The article provides a corporate overview of IPSC, highlighting their strategic vision to advance allogeneic cell therapies for cancer. It outlines progress in the development of various candidates, including CNTY-101 and CNTY-102, which are designed to improve treatment efficacy and durability. The company boasts a robust financial foundation, with significant cash reserves and an operational GMP manufacturing facility. Additionally, IPSC's Allo-Evasion technology aims to overcome limitations seen in previous therapies, positioning the company as a potential leader in the field.
Read more →IPSCCentury Therapeutics Reports Full Year 2022 Financial Results and Provides Business Updates - Phase 1 ELiPSE-1 trial of CNTY-101 in relapsed/refractory CD19 positive B-cell lymphomas underway - - Ended 2022 with cash, ca
Century Therapeutics reported its full-year 2022 financial results, highlighting the ongoing Phase 1 ELiPSE-1 trial of CNTY-101 in relapsed/refractory CD19 positive B-cell lymphomas. The company ended the year with $367.4 million in cash and cash equivalents, indicating a financial runway expected to last into 2026. Despite the financial stability, the company reported a net loss of $130.9 million, which is an increase from the previous year's loss, driven by higher operating expenses. The CEO expressed optimism regarding their next-generation iPSC technology and product candidates, aiming for progress in 2023.
Read more →IPSCCentury Therapeutics to Present at the AACR Annual Meeting 2023
Century Therapeutics (NASDAQ: IPSC) will present preclinical data on its iPSC-derived CAR-NK cell therapy at the AACR Annual Meeting on April 17, 2023. The presentation will include an integrated multi-functional analysis aimed at nominating clinical candidate clones. This is part of the company's broader efforts to develop innovative therapies for cancer using induced pluripotent stem cells (iPSCs). The meeting will provide an opportunity to showcase their advancements in immuno-oncology.
Read more →IPSCCentury Therapeutics to Present at Upcoming Investor Conferences
Century Therapeutics (NASDAQ: IPSC) announced participation in upcoming investor conferences, including the H.C. Wainwright Cell Therapy Virtual Conference on February 28 and the Cowen 43rd Annual Health Care Conference on March 6, 2023. The management team will engage in presentations that are aimed at increasing investor awareness of the company's advancements in induced pluripotent stem cell (iPSC) therapies. A replay of the sessions will be available on the company’s website for a period of 30 days. The company focuses on developing innovative cell therapy products for cancer treatment.
Read more →IPSCCentury Therapeutics Announces First Patient Dosed in First-In-Human Phase 1 ELiPSE-1 Trial Evaluating CNTY-101 in Relapsed or Refractory CD19 Positive B-cell Lymphomas
Century Therapeutics has announced the dosing of the first patient in its Phase 1 ELiPSE-1 trial for CNTY-101, targeting relapsed or refractory CD19 positive B-cell lymphomas. This investigational cell therapy features Allo-Evasion™ technology designed to resist immune rejection and improve the therapy's effectiveness. The trial will assess safety, tolerability, and efficacy while exploring a multi-dosing strategy. This marks a significant milestone for the company as it seeks to advance its innovative approach to cancer treatment.
Read more →IPSCCorporate OverviewJanuary 2023 2 Forward-looking statementsThis presentation contains forward-looking statements within the meaning of, and made pursuant to the safe harbour provisions of, The Private Securities Litigati
IPSC is advancing its allogeneic cell therapy platform with multiple development candidates, including CNTY-101 and CNTY-107, which show promising initial clinical data. The company has a strong cash runway into 2026, allowing for continued investment in research and development. IPSC aims to enhance its product offerings by prioritizing operational efficiencies and has established a robust manufacturing infrastructure. Their collaboration with BMS to focus on AML and multiple myeloma exemplifies their strategic direction in cancer therapies.
Read more →IPSCCentury Therapeutics Announces Internal Portfolio Prioritization to Extend Cash Runway Into 2026
Century Therapeutics announced a strategic portfolio prioritization, focusing on key product candidates like CNTY-101 and CNTY-107, extending their cash runway into 2026. This strategic shift includes a 25% reduction in workforce and the de-prioritization of CNTY-103 for glioblastoma treatments. The company's partnered programs with Bristol Myers Squibb remain unaffected, and leadership changes occur as they consolidate operations in Philadelphia.
Read more →IPSCCentury Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
Century Therapeutics, a biotechnology company focused on iPSC-derived cell therapies, announced that its CEO, Lalo Flores, will present at the 41st Annual J.P. Morgan Healthcare Conference on January 11, 2023. The presentation will highlight the company's innovative approaches in immuno-oncology. Century aims to overcome existing challenges in cancer treatment through its genetically engineered therapies designed for targeting various types of tumors. The event will also include a live webcast, providing broader access to their developments.
Read more →IPSCCorporate OverviewNovember 2022 2 Forward-looking statementsThis presentation contains forward-looking statements within the meaning of, and made pursuant to the safe harbour provisions of, The Private Securities Litigat
Starting dose Schedule A (n=3/cohorta) Schedule B (n=3/cohorta) Day 15 Day 8 DL2 (300e6) DL2 (300e6) DL2 (300e6) DL3 (1000e6) DL3 (1000e6) DL3 (1000e6) Schedule B opens with ~1/3 schedule A MTD One overall CNTY-101 RP2R will be declared per SRC recommendation, based on both Sched
Read more →IPSC▲ +5.2%on this news
Century Therapeutics to Present at the Piper Sandler 34th Annual Healthcare Conference
PHILADELPHIA, Nov. 22, 2022 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology, today announced that Lalo Flores, Ph.D., Chief Executive Officer, wi
Read more →IPSC▼ -5%on this news
Century Therapeutics Announces Presentation of Preclinical Data at the SITC 37th Annual Meeting and Provides Pipeline Updates
- Preclinical data support next generation platform for iPSC-derived NK cells with multiple gene edits to improve persistence and anti-tumor efficacy - - iPSC-derived CAR gamma delta T cells shown to effectively control solid tumors as monotherapy and in combination with a thera
Read more →IPSC▲ +15.1%on this newsshared move
Century Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Updates - Phase 1 ELiPSE-1 trial of CNTY-101 in relapsed/refractory CD19 positive B-cell malignancies expected to begin imminently -
Century Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Updates Phase 1 ELiPSE-1 trial of CNTY-101 in relapsed/refractory CD19 positive B-cell malignancies expected to begin imminently - Ended third quarter 2022 with cash, cash equivalents, and
Read more →IPSCCentury Therapeutics to Host Virtual Research and Development Day on November 11, 2022
PHILADELPHIA, Nov. 02, 2022 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology, today announced that it will host a virtual Research and Development
Read more →IPSCCentury Therapeutics to Present at the SITC 37th Annual Meeting
PHILADELPHIA, Oct. 05, 2022 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology, today announced that preclinical data from the Company’s iPSC-based
Read more →IPSCCentury Therapeutics Announces Appointment of Daphne Quimi and Timothy Walbert to its Board of Directors
PHILADELPHIA, Oct. 03, 2022 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology, today announced the appointment of Daphne Quimi and Timothy Walbert
Read more →IPSCCentury Therapeutics to Present at Chardan’s 6th Annual Genetic Medicines Conference
PHILADELPHIA, Sept. 26, 2022 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology, today announced that Lalo Flores, Ph.D., Chief Executive Officer, w
Read more →IPSCCorporate Overview September 2022 2 Forward - looking statements This presentation contains forward - looking statements within the meaning of, and made pursuant to the safe harbour provisions of, The Private Securities
Corporate Overview September 2022 2 Forward - looking statements This presentation contains forward - looking statements within the meaning of, and made pursuant to the safe harbour provisions of, The Private Securities Litigation Reform Act of 1995. All statements contained in
Read more →IPSCCentury Therapeutics to Present at the H.C. Wainwright 24th Annual Global Investment Conference
PHILADELPHIA, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology, today announced that Adrienne Farid, Ph.D., Chief Operations Office
Read more →IPSCCentury Therapeutics Receives Study May Proceed Notification from FDA for CNTY-101, the First Allogeneic Cell Therapy Product Candidate Engineered to Overcome Three Major Pathways of Host vs Graft Rejection - Investigati
Century Therapeutics Receives Study May Proceed Notification from FDA for CNTY-101, the First Allogeneic Cell Therapy Product Candidate Engineered to Overcome Three Major Pathways of Host vs Graft Rejection - Investigational New Drug Application for CNTY-101, a CAR-iNK produc
Read more →IPSCCentury Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Updates - Following the recent submission of the IND application for CNTY-101 and pending FDA clearance, the Phase 1 ELiPSE-1 trial
Century Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Updates - Following the recent submission of the IND application for CNTY-101 and pending FDA clearance, the Phase 1 ELiPSE-1 trial in relapsed/refractory lymphoma is on track to commence
Read more →IPSC▼ -6.4%on this news· ran to -17% by day 3
Century Therapeutics Announces Its Addition to the Russell Microcap Index
PHILADELPHIA, June 24, 2022 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology, today announced that it is set to join the Russell Microcap Index at
Read more →IPSC▲ +5.6%on this newsshared move
Century Therapeutics to Present at the LifeSci Partners 2nd Annual Genetic Medicines Symposium
PHILADELPHIA, June 21, 2022 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology, today announced that Lalo Flores, Ph.D., Chief Executive Officer, wi
Read more →IPSC▼ -6.4%on this news
Virtual R&D Day
Coli and is Functionally Equivalent to Industry Standard Cpf1 Knock-out efficiency of MAD7 is as efficient as Cpf1 Purified MAD7 activity is maintained for >6 months at -80C Multi-step column purification yields homogenous MAD7 protein MAD7 RNPs function comparably to Cpf1 in iPS
Read more →IPSCCentury Therapeutics to Host Virtual Research and Development Day on June 13, 2022
PHILADELPHIA, June 06, 2022 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology, today announced that it will host a virtual Research and Development
Read more →IPSC▲ +9.8%on this news
Century Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Updates - Phase 1 ELiPSE-1 trial of CNTY-101 in relapsed/refractory lymphoma expected to commence in the second half of 2022 followi
Century Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Updates - Phase 1 ELiPSE-1 trial of CNTY-101 in relapsed/refractory lymphoma expected to commence in the second half of 2022 following IND submission in mid 2022- - Ended first quarter 202
Read more →IPSCCentury Therapeutics to Present at the ASGCT 25th Annual Meeting
PHILADELPHIA, May 02, 2022 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology, today announced that preclinical data on MAD7, a novel CRISPR nucleas
Read more →IPSCCentury Therapeutics to Present at the Chardan Genetic Medicines and Cell Therapy Manufacturing Summit
PHILADELPHIA, April 18, 2022 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology, today announced that members of the management team will present at
Read more →IPSCCentury Therapeutics to Present at the 21st Annual Needham Virtual Healthcare Conference
PHILADELPHIA, April 06, 2022 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology, today announced that Lalo Flores, Ph.D., Chief Executive Officer, w
Read more →IPSCCentury Therapeutics to Present at the H.C. Wainwright Gene Therapy and Gene Editing Conference
PHILADELPHIA, March 23, 2022 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology, today announced that Lalo Flores, Ph.D., Chief Executive Officer, w
Read more →IPSCCentury Therapeutics Reports Fourth Quarter and Year-end 2021 Financial Results and Provides Business Updates IND submission for lead program CNTY-101 on track for mid 2022; Phase 1 ELiPSE-1 trial of CNTY-101 in relapsed
Century Therapeutics Reports Fourth Quarter and Year-end 2021 Financial Results and Provides Business Updates IND submission for lead program CNTY-101 on track for mid 2022; Phase 1 ELiPSE-1 trial of CNTY-101 in relapsed/refractory lymphoma expected to commence after IND submi
Read more →IPSCCentury Therapeutics to Present at the 11th Annual SVB Leerink Global Healthcare Conference
PHILADELPHIA, Feb. 09, 2022 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology, today announced that members of the senior management team will part
Read more →IPSCJ.P. MORGAN ANNUAL HEALTHCARE CONFERENCE January 2022 2 2 FORWARD-LOOKING STATEMENTS This presentation contains forward-looking statements within the meaning of, and made pursuant to the safe harbour provisions of, The P
Building on a strong foundation, we believe we are poised to lead in iPSC derived cell therapies and disrupt the cell therapy field First candidate CNTY-101 expected to enter the clinic in 2H2022 Well capitalized with cash runway into 2025 Strong pipeline expected to deliver 5 IN
Read more →IPSC▲ +14.5%on this newsshared move
Century Therapeutics and Bristol Myers Squibb Enter into a Strategic Collaboration to Develop iPSC-derived Allogeneic Cell Therapies
- Collaboration brings together Century’s industry leading iPSC-derived allogeneic cell therapy platform with Bristol Myers Squibb’s expertise in cell therapy and oncology drug development - - First two programs include a program in acute myeloid leukemia and a program in multip
Read more →IPSCCentury Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference
PHILADELPHIA, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology, today announced that Lalo Flores, Ph.D., Chief Executive Officer, wi
Read more →IPSC▲ +8.9%on this news
Century Therapeutics Added to the NASDAQ Biotechnology Index
PHILADELPHIA, Dec. 17, 2021 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology, today announced it has been selected for addition to the NASDAQ Biot
Read more →IPSCCentury Therapeutics Announces Presentation of Data at the 63rd American Society of Hematology Annual Meeting and Provides Pipeline Updates
- In vivo data presented at ASH Annual Meeting demonstrated strong antitumor activity against human lymphoma cell lines with CNTY-101 - - Company announces plans for Phase 1 ELiPSE-1 trial of CNTY-101 in relapsed/refractory lymphoma; IND submission on track for mid-2022 - - Dat
Read more →IPSCVIRTUAL R&D UPDATE
Starting Schedule B Dose: 1/3 current dose, given 3 times, 1 week apart Part 1 With IL-2 Part 2 Dose Level (DL) 30e6 x1 Schedule A 100e6 x1 1000 e6 x1 300e6 x1 RP2R To N=20 subjects* 100e6 q w x3 1000 e6 q w x3 300e6 q w x3 Schedule B Fallback Dose Starting Dose DL-1 DL1 DL2 DL3
Read more →IPSC▼ -17.6%on this news
Century Therapeutics to Participate in the Piper Sandler 33rd Annual Virtual Healthcare Conference
PHILADELPHIA, Nov. 22, 2021 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology, today announced that members of the senior management team have part
Read more →IPSCCORPORATE OVERVIEW November 2021 2 2 FORWARD - LOOKING STATEMENTS This presentation contains forward - looking statements within the meaning of, and made pursuant to the safe harbour provisions of , The Private Securitie
CORPORATE OVERVIEW November 2021 2 2 FORWARD - LOOKING STATEMENTS This presentation contains forward - looking statements within the meaning of, and made pursuant to the safe harbour provisions of , The Private Securities Litigation Reform Act of 1995. All statements contained i
Read more →IPSCCentury Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Updates Lead program, CNTY-101 in relapsed/refractory non-Hodgkin's lymphoma, remains on track for IND filing in mid-2022 Pre-clinic
Century Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Updates Lead program, CNTY-101 in relapsed/refractory non-Hodgkin's lymphoma, remains on track for IND filing in mid-2022 Pre-clinical data from CNTY-101 program and CAR-iT platform to be
Read more →IPSCCentury Therapeutics to Present at the 63rd American Society of Hematology Annual Meeting and Host Virtual Research & Development Update
PHILADELPHIA, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology, today announced that preclinical data from the Company’s CNTY-101 pr
Read more →IPSCCORPORATE OVERVIEW October 2021 2 2 FORWARD-LOOKING STATEMENTS This presentation contains forward-looking statements within the meaning of, and made pursuant to the safe harbour provisions of, The Private Securities Liti
Methodology developed at Century - HDR technology enables precise gene KOs and transgene KIs - CRISPR protein and guide RNAs delivered using RNP (non-viral) Fully characterized, homogeneous drug products - Sequential gene editing steps allow: - Introduction of multiple gene modif
Read more →IPSCCentury Therapeutics and Outpace Bio Enter Research Collaboration in CAR Engineering
Collaboration enables Century to explore Outpace’s protein solutions for cell therapy to enhance functionality of iPSC platform Initial program to focus on hematological malignancies with option to expand to additional candidates PHILADELPHIA, Oct. 07, 2021 (GLOBE NEWSWIRE) --
Read more →IPSC▼ -15.4%on this news· ran to -29% by day 3
Century Therapeutics Announces Its Addition to the Russell 2000 Index
PHILADELPHIA, Sept. 17, 2021 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology, today announced that it will be added to the small-cap Russell 2000
Read more →IPSCCentury Therapeutics Reports Second Quarter 2021 Financial Results and Business Updates Continued Company investment across our iPSC platforms, programs and manufacturing Lead program, CNTY-101, remains on track for IND
Therapeutics Reports Second Quarter 2021 Financial Results and Business Updates Continued Company investment across our iPSC platforms, programs and manufacturing Lead program, CNTY-101, remains on track for IND filing in mid-2022 Recent IPO with net proceeds of approximate
Read more →IPSCCentury Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
PHILADELPHIA, June 22, 2021 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology, today announced the closing of its initial public offering of 12,132
Read more →IPSCCentury Therapeutics Announces Pricing of Initial Public Offering
PHILADELPHIA, June 17, 2021 (GLOBE NEWSWIRE) -- Century Therapeutics, an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology, today announced the pricing of its initial public offering of 10,550,000 shares of
Read more →IPSCCentury Center Chiropractic Celebrates Over 25 Years of Chiropractic Service to the Atlanta Community
ATLANTA, Feb. 12, 2017 (GLOBE NEWSWIRE) -- Chiropractor Dr. Jared Simon has served the chiropractic needs of residents in and around Atlanta and has partnered to improve the quality of lives of neighbors for more than 25 years. Dr. Simon has had a distinguished career and residen
Read more →IPSCCentury Center Chiropractic Celebrates 23 Years of Service to Atlanta Area
ATLANTA, Sept. 27, 2015 (GLOBE NEWSWIRE) -- Atlanta, Georgia chiropractor, Dr. Jared Simon, of Century Center Chiropractic began his practice in 1992 with the goal of freeing people from pain and has been dedicated to the cause for the past 23 years. Over the years his practice m
Read more →IPSCCentury Center Chiropractic Announces New High-Tech Equipment for Enhanced Pain Relief
ATLANTA, April 26, 2015 (GLOBE NEWSWIRE) -- Century Center Chiropractic announced that the practice has added a quantum intersegmental traction table as well as a Quattro 2.5 interferential muscle stimulation machine. The practice is now able to provide muscle stimulation to pati
Read more →Competitive Position
How IPSC ranks across every disease it competes inCompetitive Position is a premium feature
See how IPSC ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial